AC Immune (ACIU) has released an update.
AC Immune’s financial statements reveal a consistent total asset value with a slight decrease between December 2023 and March 2024, from CHF 182,814 to CHF 167,281. The company experienced a net loss for the period ending March 31, 2024, amounting to CHF 17,862, with a basic and diluted loss per share of CHF 0.18. Despite research and development expenses contributing to the loss, the financial income and net financial result were positive, signifying some financial resilience.
For further insights into ACIU stock, check out TipRanks’ Stock Analysis page.
